retatrutide regulatory approval Weight Loss Blog – Maryland Trim Clinic ⚠️ BEWARE OF RETATRUTIDE SOLD

In a randomized, single-blind, 24-week study, participants assigned to dual therapy of 2 mg weekly of the GLP-1 receptor agonist exenatide (Bydureon, AstraZeneca) and 10 mg daily of the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) lost more weight than those taking either agent alone or those receiving dapagliflozin and metformin extended-release (Xigduo XL, AstraZeneca) or phentermine/topiramate extended-release (Qsymia, Vivus)

Some people report feeling slightly more tired than usual

Metformin is more likely to be covered by health insurance, says Ponder

25 , 10751090 e1075 (2017)

Blood or mucus in the stool